Literature DB >> 12924646

Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.

Atsushi Nanashima1, Kenji Tanaka, Hiroyuki Yamaguchi, Shinichi Shibasaki, Shigeyuki Morino, Megumi Yoshinaga, Terumitsu Sawai, Tohru Nakagoe, Hiroyoshi Ayabe.   

Abstract

This study was designed to provide a histopathological analysis focusing on fibrosis (staging) and necroinflammatory reaction (grading, hepatitis activity index: HAI) in noncancerous liver tissue, and mitotic index (MI) in cancerous liver tissue to predict prognosis in 81 patients with chronic hepatitis or cirrhosis who underwent hepatectomy for hepatocellular carcinoma (HCC). The incidence of grade 2/3 and higher HAI was higher in patients with viral hepatitis C. The incidence of grade 2/3 was associated with vascular invasion of HCC, postoperative liver dysfunction, and cancer recurrence. Higher MI (> or = 5) was significantly associated with vascular invasion, poor histological differentiation, and recurrence rate (P < 0.05). Multivariate analysis showed that higher grade was the factor strongly associated with cancer recurrence (odds ratio: 10.621, P = 0.006). Higher MI correlated with overall patient survival (P < 0.05) by univariate analysis. Grading and MI are the useful prognostic markers for predicting tumor recurrence and patient survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12924646     DOI: 10.1023/a:1024759606402

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  What patients can survive disease free after complete resection for hepatocellular carcinoma?: A multivariate analysis.

Authors:  M Takata; N Yamanaka; T Tanaka; J Yamanaka; S Maeda; E Okamoto; H Yasojima; K Uematsu; H Watanabe; Y Uragari
Journal:  Jpn J Clin Oncol       Date:  2000-02       Impact factor: 3.019

2.  Influence of associated viral hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  S Ko; Y Nakajima; H Kanehiro; T Kin; Y Aomatsu; A Yoshimura; J Taki; K Yagura; K Ohashi; H Nakano
Journal:  World J Surg       Date:  1996-10       Impact factor: 3.352

3.  Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma.

Authors:  A Tannapfel; F Geissler; F Köckerling; A Katalinic; J Hauss; C Wittekind
Journal:  J Pathol       Date:  1999-03       Impact factor: 7.996

Review 4.  Management of viral hepatitis B.

Authors:  Chutima Pramoolsinsup
Journal:  J Gastroenterol Hepatol       Date:  2002-02       Impact factor: 4.029

5.  Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining.

Authors:  T Nagao; F Kondo; T Sato; Y Nagato; Y Kondo
Journal:  Hum Pathol       Date:  1995-03       Impact factor: 3.466

6.  [Prognostic significance of proliferation markers in hepatocellular carcinoma (HCC)].

Authors:  J Ebelt; M Neid; A Tannapfel; H Witzigmann; J Hauss; F Köckerling; C Wittekind
Journal:  Zentralbl Chir       Date:  2000       Impact factor: 0.942

7.  Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis.

Authors:  S Ko; Y Nakajima; H Kanehiro; M Hisanaga; Y Aomatsu; T Kin; K Yagura; T Ohyama; K Nishio; K Ohashi; M Sho; T Yamada; H Nakano
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

8.  Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology.

Authors:  O Nakashima; M Kojiro
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

9.  Fibrosis accelerates the development of enzyme-altered lesions in the rat liver.

Authors:  I Sakaida; K Hironaka; K Uchida; C Suzuki; K Kayano; K Okita
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

10.  Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C.

Authors:  S Kubo; T Yamamoto; T Ikebe; T Shuto; K Hirohashi; H Tanaka; T Tsukamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1999-10
View more
  4 in total

1.  Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.

Authors:  Arne Dettmer; Timm-D Kirchhoff; Michael Gebel; Lars Zender; Nisar-P Malek; Bernhard Panning; Ajay Chavan; Herbert Rosenthal; Stefan Kubicka; Susanne Krusche; Sonja Merkesdal; Michael Galanski; Michael-P Manns; Joerg-S Bleck
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

2.  The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy.

Authors:  Sang Yun Ha; Misun Choi; Taebum Lee; Cheol-Keun Park
Journal:  Cancer Res Treat       Date:  2015-03-18       Impact factor: 4.679

3.  Usefulness of serum Mac-2 binding protein glycosylation isomer in patients undergoing hepatectomy: A case controlled study.

Authors:  Masahide Hiyoshi; Koichi Yano; Atsushi Nanashima; Makoto Ikenoue; Naoya Imamura; Yoshiro Fujii; Takeomi Hamada; Takahiro Nishida
Journal:  Ann Med Surg (Lond)       Date:  2019-10-17

4.  Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma.

Authors:  Marcone Loiola Dos Santos; Andressa França; Antônio Carlos Melo Lima Filho; Rodrigo M Florentino; Paulo Henrique Diniz; Fernanda Oliveira Lemos; Carlos Alberto Xavier Gonçalves; Vitor Lima Coelho; Cristiano Xavier Lima; Giselle Foureaux; Michael H Nathanson; Paula Vieira Teixeira Vidigal; M Fátima Leite
Journal:  Oncol Lett       Date:  2021-11-25       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.